Valuation: Beta Bionics, Inc.

Market Cap 857M 734M 687M 629M 1.18B 82B 1.2B 8.12B 3.16B 41.19B 3.22B 3.15B 136B P/E 2026 *
-8.92x
P/E 2027 * -8.86x
Enterprise Value 723M 620M 580M 531M 996M 69.21B 1.01B 6.85B 2.67B 34.77B 2.72B 2.66B 115B EV / Sales 2026 *
5.4x
EV / Sales 2027 * 4.36x
Free-Float
98.92%
Yield 2026 *
-
Yield 2027 * -
1 day-2.21%
1 week+8.42%
Current month+48.48%
1 month+8.12%
3 months+79.55%
6 months+39.05%
Current year-37.48%
1 week 16.99
Extreme 16.99
20.74
1 month 12.73
Extreme 12.73
20.74
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 14/08/2022
Director of Finance/CFO 37 31/07/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 31/01/2020
Director/Board Member 50 14/08/2022
Director/Board Member 63 30/09/2024
Date Insider Type Main position Quantity % Market Cap.
24/06/26 Sell

Executive/Senior Manager

-1,258 0.0028%
27/02/26 Sell

Executive/Senior Manager

59,813 0.1359%
27/02/26 Free

Chief Executive Officer

287,944 0.6541%
Change 5-day change 1-year change 3-year change Capi.($)
-2.21%+8.42%+12.79% - 857M
+0.27%+6.97%+30.08%+18.23% 233B
+1.36%+8.10%+7.33%-12.52% 154B
+1.16%-3.98%-19.38%+32.14% 134B
+2.03%-2.82%-52.12%-0.10% 73B
-0.04%-1.98%+10.63%+17.63% 51.75B
+0.98%+2.26%-15.88%-11.61% 52.24B
+1.73%+7.05%+35.72%+33.77% 44.91B
+1.49%-0.36%+41.41%+53.72% 40.35B
+1.03%+1.53%+2.28%+8.48% 33.8B
Average +0.82%+2.42%+5.29%+15.53% 81.72B
Weighted average by Cap. +1.01%+3.00%+5.89%+13.33%

Financials

2026 *2027 *
Net sales 134M 115M 107M 98.23M 184M 12.81B 187M 1.27B 494M 6.43B 503M 492M 21.28B 180M 154M 144M 132M 247M 17.19B 251M 1.7B 663M 8.63B 675M 660M 28.56B
Net income -94.91M -81.3M -76.07M -69.63M -131M -9.08B -132M -899M -350M -4.56B -356M -349M -15.09B -96.44M -82.61M -77.29M -70.75M -133M -9.23B -135M -913M -356M -4.64B -362M -354M -15.33B
Net Debt -134M -115M -107M -98.1M -184M -12.79B -187M -1.27B -494M -6.43B -502M -491M -21.26B -73.32M -62.81M -58.77M -53.79M -101M -7.02B -102M -694M -271M -3.52B -275M -269M -11.66B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
21/08/26 US$19.05 -2.21% 496,596
20/08/26 US$19.48 -2.65% 1,933,847
19/08/26 US$20.01 +5.21% 1,947,730
18/08/26 US$19.02 +8.31% 1,975,998
17/08/26 US$17.56 -0.06% 1,267,696
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
19.05USD
Average target price
20.31USD
Spread / Average Target
+6.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock